Publications by authors named "H Nakamae"

Background: Patients with adult T-cell leukemia/lymphoma (ATL) are considered to have worse outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT) than patients with other hematological malignancies, owing to high risk of relapse and immunocompromised status. However, no studies have compared transplant outcomes between patients with ATL and those with other hematological malignancies using a large-scale database.

Objectives: To compare transplant outcomes between patients with ATL and those with other leukemias and to identify factors contributing to worse transplant outcomes in ATL patients.

View Article and Find Full Text PDF
Article Synopsis
  • * The research included 707 adults and found that the 5-year progression-free survival (PFS) rate was 18.8%, with overall survival at 22.0%, and identified key factors affecting outcomes, such as male sex, poor performance status, karyotype risk, and blasts in the blood.
  • * These findings provide valuable insights into the prognosis and treatment strategies for R/R AML, influencing future
View Article and Find Full Text PDF
Article Synopsis
  • The study compares outcomes of unrelated cord blood transplantation (UCBT) and haploidentical transplantation with posttransplant cyclophosphamide (PTCy-haplo) in patients without a matched donor, focusing on the impact of CD34 cell counts in cord blood.
  • Data from 2014 to 2020 was analyzed, categorizing UCBT cases into those with high (≥0.84 × 10/kg) and low (<0.84 × 10/kg) CD34 cell counts, revealing better neutrophil engraftment in PTCy-haplo compared to both UCB groups.
  • While UCB-H showed similar nonrelapse mortality (NRM) and overall survival
View Article and Find Full Text PDF

This study aimed to investigate the prognostic relevance of cytogenetic risk in 9826 adults with acute myeloid leukemia (AML) who underwent allogeneic hematopoietic cell transplantation (HCT) during the first or second complete remission. The 5-year probabilities of overall survival (OS) were 66%, 61%, and 47% (P < 0.001), the cumulative incidences of relapse were 14%, 19%, and 32% (P < 0.

View Article and Find Full Text PDF